METHOD FOR LABELLING ANTIBODIES WITH A METAL ION

Abstract: A method for labelling a sulfhydryl containing antibody or antibody fragment with technetium-99m is disclosed. The method comprises contacting an antibody mixture comprised of a sulfhydryl containing antibody or antibody fragment and a reducing agent with technetium-99m in an oxidized state. The antibody mixture further contains a water soluble ligand. A one vial method and kit for labeling a sulfhydryl containing antibody or antibody fragment with technetium-99m is also disclosed.

Description: METHOD FOR LABELING ANTIBODIES WITH A METAL ION Background of the Invention Proteins have been labeled with various radio¬ metals and other radioisotopic elements for u * δe in i munodiagnostic and immunotherapeutic procedures. Some radiometals have superior properties for use in these techniques. Technetium-99m is an ideal radionuclide for scintigr ' aphic imaging because of its nuclear properties. It has a single photon energy of 140keV, a half-life of about 6 hours, and it is readily avai .lable from a 99Mo-99mTc generator. Rhenium radioisotopes are beta-emitters which can kill target cells and thus are useful in therapy. Rhenium-186 and -188 also have gamma emission which, as an added feature, allows it to be imaged by scintigraphic techniques. Two general approaches have been taken to label proteins such as antibodies with radiometals. The first is the direct labeling method by which the radiometal is bound to the protein molecule itself. The second is the indirect labeling method in which a chelating agent is coupled to the protein and the radiometal is attached to the protein via the chelating agent. Rhodes discloses a method of direct labeling of protein with technetium-99m which involves ligand solid phase exchange. See U.S. Patent 4,305,922. According to the method of Rhodes, pertechnetate is reduced to technetium IV and then applied onto a Sephadex column. The reduced technetium-99m binds to the Sephadex material. A solution of the protein to be labeled is poured onto the top of the Sephadex column where it is allowed to remain so that ligand exchange occurs. As a result, the technetium-99m is transferred preferentially from the Sephadex material to the protein. The protein may be pretreated with a stannous chloride (a procedure called "pretinhing") to enhance transfer of the radiometal to the protein. See U.S. Patent No. 4,424,200. Various attempts have been made to label proteins with radiometals by the indirect approach. In one such approach, a chelating agent such a diethylenetriaminepentaacetic acid (DTPA) is con¬ jugated onto the protein and then the metal ion is labeled onto the chelating agent attached to the protein molecule. For example, Khaw et al. , Science 209: 295-297 (1980) discloses antibodies to cardiac myosin labeled with indium-Ill via DTPA and use of the labeled antibodies to image for myocardial infarction. See also, Krejcarek et a^. , Biochem. Biophys. Res. Commun. 77: 581-585 (1977) ; Childs, R.L. and Hnatowich, D.J. , J. Nucl. I-Ted. 26: 293 (1985) . In a more recent approach, Fritzberg et al. describe the use particular dia inodithiol and diamidodithiol groups, as a chelating agents. Fritzberg et al, J. Nucl. Med. £7:957 (1986); European Patent Application 86100360.6. Various degrees of success have been achieved with both the direct and indirect methods of labeling proteins with radiometals. However, the labeled product is often unstable ijji vivo. Further, techniques for purifying the labeled product before use are often required. A need exists for improved methods for stably labeling proteins for radioimmunodiagnostic and radioimmunotherapeutic procedures. Summary of the Invention This invention pertains to a simple, rapid and efficient method of labeling sulfhydryl-containing antibodies or antibody fragments with the radio¬ metals technetium-99m rhenium-186, rhenium-188, rhenium-189 and rhenium-191. In general, the method comprises: a. forming an aqueous mixture of (i) the radiometal in an oxidized form; and (ii) a reducing agent and a water-soluble ligand which is capable of forming a stable complex with the radiometal in its reduced state and quantitatively exchanging the radiometal with a sulfhydryl-containing antibody; and b. contacting the mixture with a sulfhydryl- containing antibody or antibody fragment to produce a radiometal-labeled antibody or antibody fragment. Technetium-99m labeled antibodies or antibody fragment are useful for radioimmunodiagnostic purposes such as i munoscintigraphy. The rhenium labeled antibodies or antibody fragments can be used for therapy. The preferred ligand is a polyhydroxy- dicarboxylic acid or salt thereof having a molecular weight of less than about 10,000 daltons. An especially preferred ligand is saccharic acid. Saccharic acid quickly and stably complexes with technetium-99m in its reduced state and without the formation of significant ' technetium colloids. When contacted with a sulfhydryl-containing antibody, Technetium-99mm is preferentially transferred to the antibody to form a stable labeled antibody. The preferred reducing agents for use in the method are stannous reducing agents such as stannous chloride. These reagents effectively reduce tech¬ netium and are pharmacologically acceptable. The method of this invention can be used to label whole antibodies (e.g., IgG) or antibody fragments (e.g.. Fab'). Whole antibodies can be reduced with the reducing agent dithiothreitol (DTT) for example, to produce sulfhydryl containing antibodies. Fab' fragments are especially suited for labeling by the procedure. Under nonoxidizing conditions, these fragments contain free sulfhydryl groups (as they are produced by reduction of disul- fide bridges present in F(ab) ' fragments. For most radioimmunodiagnostic techniques, antibody fragments such as Fab 1 fragments are preferred and thus, the labeling procedure of this invention is particularly suited for preparing radiopharmaceuticals for these techniques. The method of radiolabeling antibody or anti¬ body fragments with the designated radiometals can be performed as a simple two-vial procedure. For this purpose, kits can be provided with the reagents in a form ready for use on site by the clinician. For example, such a kit can include a first vial containing a reducing agent (e.g. stannous ions) and the water soluble ligand (e.g. saccharic acid or a salt thereof) and a second vial containing a Fab' fragment suited for the particular diagnostic or therapeutic procedure. The reactions are preferably carried out in an aqueous medium although the reagents may be supplied in lyophilized, frozen or aqueous form. For the preparation of technetium-99m labeled fragments, technetiu_rt-99m (generally in the form of pertechnetate) is added to the first vial and then the contents of the first and second vial are mixed and incubated for a time sufficient to effect a quantitative transfer of the technetium-99m to the Fab* fragment. The composition can then be injected into the patient without purification. For radiolabeling with rhenium, rhenium isotopes (in the form of a perrhenate) are used in place of the technetium. The rhenium labeled Fab' fragment is also suitable for injection without purification. In a preferred embodiment, the radiolabeling can be performed in a single vial. A kit can include a single vial containing an antibody mixture comprised of a sulfhydryl containing antibody or antibody fragment, a reducing agent (e.g. stannous ions) , and preferably a water soluble ligand (e.g. D-glucaric acid or a salt thereof) . The antibody mixture is preferably supplied in lyophilized form although frozen or aqueous forms are also suitable. QQ*rn Technetiuιrt-99m (generally in the form of Tc pertechnetate) is added to the vial and the resulting mixture is incubated for a time sufficient to effect a quantitative transfer of the technetium-99m to the antibody or antibody fragment. This composition can then be injected into the patient without purification. The technetium-99m-labeled antibodies and antibody fragments prepared by the method of this invention can be used for. diagnostic purposes such as immunoscintigraphy of tumor, myocardial infarction, thromboses or bacterial abscess. Rhenium-labeled antibodies can be used to selectively deliver a rhenium radioisotope in vivo for therapy. The method of this invention has several important advantages. As mentioned, the ligands employed are capable of complexing technetium-99m _. quantitatively in stable form as a complex without the formation of a significant amount of technetium colloid. Upon contact with a sulfhydryl containing antibody under appropriate conditions, the complexed technetium-99m is transferred substantially quantitatively to sulfhydryl-containing antibodies so that radiodiagnostic composition can be prepared with very high specific activity. The antibody or antibody fragments labeled by the method retain their original immunoreactivity and consequently their target specificity. The radiolabeled antibody is stable in solution and in serum. When Fab' fragments labeled by the method are administered in vivo very little label accumulates in the liver which indicates that the labeled antibody is stable in vivo. In addition, the labeling method c≤m be performed rapidly (it can be completed in less than one hour) and the method can be performed at room temperature and at pH 5-9. The labeled product does not require purification before use. Brief Description of the Figures Figure 1 shows gamma scintigra s of a dog at various times after injection of technetiu_rt-99m labeled myosin-specific Fab' fragment. Figure 2 shows gamma scintigrams of the same dog taken from different views. Figure 3 shows the results of mouse biodistribution studies in blood conducted with antifibrin T2G1S prepared in single vial and double vial labeling kits. Figure 4 shows the results of mouse biodistribution studies in liver conducted with antifibrin T2G1S prepared in single vial and double vial labeling kits. Figure 5 shows the results of mouse biodistribution studies in spleen conducted with antifibrin T2G1S prepared in single vial and double vial labeling kits. Figure 6 shows the results of mouse biodistribution studies in kidney conducted with antifibrin T2G1S prepared in single vial and double vial labeling kits. Figure 7 shows the results of mouse biodistribution studies in large intestine conducted with antifibrin T2G1S prepared in single vial and double vial labeling kits. Detailed Description of the Invention In one embodiment, the method of this invention is performed by reacting Technetium-99m (in an oxidized state) with a water-soluble ligand in the presence of a reducing agent to form a stable complex between technetium-99m in a reduced state (e.g., IV or V valence state) and the ligand and then reacting the complex with an antibody or antibody fragment which contains one or more sulf¬ hydryl groups. In the preferred embodiment for labeling a sulfhydryl-containing antibody with technetium-99m, aqueous sodium 99m-pertechnetate is mixed with a aqueous solution of a stannous reducing agent and saccharic acid (or a salt thereof) to form Q a Tc-saccharate ' complex. The complex is then contacted with an Fab' fragment and incubated for a period of time and under conditions which allow an exchange of technetium-99m from the complex to the Fab' fragment to form a technetium-labeled Fab 1 fragment. The entire procedure can be conducted in less than one hour at room temperature and at a pH of about 5-9. Under these conditions an essentially complete transfer of technetium-99m (from the 99m-Tc-saccharate complex to the antibody protein) can be attained without significant loss of antibody immunoreactivity. Single vial technique This invention provides a method of radiolabeling protein in a single vial. The reduction of the oxidized form of technetium-99m and the radiolabeling reaction (i.e., the coupling of the radioisotope to protein) are achieved in the same vial. As used herein, the term "vial" refers to any type of reaction vessel and is not intended to be limiting in any way. The method is simple, efficient, and reproducible and it minimizes the safety hazards to persons performing the radiolabeling. The method of this invention is particularly suited for labeling antibodies (polyclonal and monoclonal) for diagnosis. Antibodies can be labeled by this method to a high specific activity with minimal loss of immunoreactivity. Advantages with the present one vial method over methods using two vials and other known methods for labeling with technetiuιt.-99m include: (1) Rapid labeling at ambient conditions. Labeling yields greater than 90% can be achieved in 5-15 minutes at ambient temperature without heating. The clinical advantages of near instantaneous preparation of a diagnostic agent can be substantial. (2) Stability of the lyophilized formulation of the single vial method is superior to the comparable formulation employed in a two vial method. (3) Biodistribution studies of the product resulting from the one vial method show statistically significant differences in key major organs. Uptake in kidney and liver is lower with product produced by this method. Blood clearance is ' significantly faster. These types of differences would indicate that product from this method would produce lower background, lower absorbed dose to critical organs and faster blood clearance resulting in faster ability to image areas of interest. All these would be substantial clinical advantages. (4) Plasma stability of the product is greater. This provides more viable intact product to serve as the diagnostic agent in vivo. In a preferred embodiment, an antibody mixture comprised sylfhydryl containing antibody or antibody fragment, a reducing agent and a water soluble ligand are added to a vial. Preferably, sealable reaction vial is used which has means for the introduction and withdrawal of reagent preferably under sterile or semi-sterile conditions. A vial which contains a port for syringe injection is preferred. All reagents can be injected and withdrawn from the reaction vial by syringe, thereby reducing the risk of exposure to radio- or biohazardous reagents. In a most preferred embodiment, the mixture is lyophilized and the vial is presealed and supplied for use in that form. In order to label the antibody or antibody fragment, technetium-99m in an oxidized state is contacted with the antibody mixture. The radiolabelling reaction is then allowed to proceed. The duration and condition of incubation are not critical. Preferably, incubation is conducted for a period from about one minute to about 60 minutes, and most preferably from about 5 minutes to about 30 minutes. After completion of the labeling reaction, the labeled antibody or antibody fragment is withdrawn from the vial. No separation or purification is required. The entire procedure can be conducted in less than 15 minutes at ambient temperature and at a pH of about 5-9. Under these conditions an essentially complete labeling of the antibody or antibody fragment with technetium-99m can be attained without significant loss of antibody immunoreactivity. The various reagents used in the method and the parameters of the method are discussed in detail below. The Ligands In general, the ligands useful in the method of this invention are water-soluble (or can be made water soluble) chelators which are capable of complexing technetium-99m or any of the rhenium radioisotopes in their reduced state to form a stable metal ion/1igand complex. The complex is capable of exchanging the technetium-99 with a sulfhydryl containing antibody or antibody fragment. Some of the ligands which can be used in the labeling method of this invention are represented by compounds (including physiologically acceptable salts thereof) having the general formula: R l R-(CHX) m -(C) p -(CHY) n -R « R 2 where X and Y are OH or NH_; R and R' independently H, COOH, or CH 2 OH or R and R' taken together can form a ring or bi-or multidentate ligand; m and n are 0-10, such that m+n is at least 2; R. and R_ are independently H, lower alkyl, substituted lower alkyl, aryl and lower alkylaryl; and p is 0 or 1 provided that, when p is 1, m and n independently are at least 1. Some of the preferred water soluble ligands for use in the method are represented by the formula: R-(CHOH) n -R' wherein R and R 1 are COOH or CH-OH, and n=2-10 Among the ligands represented by this formula, polyhydroxydicarboxylic acids having a molecular weight of less than about 10,000 daltons are most preferred. Some specific examples of these types of ligands are saccharic acid, glucoheptonic acid, tartaric acid, galactaric acid, arabonic acid, and salts thereof. The particularly preferred ligand for use in this method is saccharic acid. As mentioned, saccharic acid complexes with technetium-99m quickly to form a stable technetium-99m-saccharate complex. Upon contact with a sulfhydryl-containing antibody or antibody fragment, substantially quantitative transfer of technetium-99m from the complex to the protein is achieved rapidly and under mild con¬ ditions. As described below, it is believed that the technetium-99m is preferentially transfered to favored binding sites on the protein molecules. This preferential transfer results in a labeled antibody or fragment which is i munoreactive and exceptionally stable iri vivo. Reducing Agents Reducing agents for use in the method are physiologically acceptable for reducing tech- netium-99m from its oxidized state to the IV or IV oxidization state or for reducing rhenium from its oxidized state. Examples of reducing agents which can be used in the method are stannous chloride, stannous fluoride, stannous tartarate, and sodium dithionite; the preferred agents are stannous reducing agents especially stannous chloride. Radioisotopes of technetium and rhenium The source of Technetium-99m should preferably be water soluble. Preferred sources are alkali and alkaline earth metal pertechnetate (TcO ~) . The technetium-99m is most preferably obtained in the form of fresh sodium pertechnetate from a sterile technetium-99m generator (e.g., from a conventional 99Mo/99mTc generator) . Any other source of physio¬ logically acceptable technetium-99m, however, may be used. Rhenium radioisotopes (the isotopes 186, 188, 189 and 191) in the form of perrhenate salts can be produced by suitable reactor technology or made by a suitable generator. The perrhenate salts are stable, soluble salts and behave similarly to pertechnetate. Perrhenate requires a slightly greater reduction potential to reduce, and tends to return to perrhenate in the presence of oxygen more readily than pertechnetate. For this reason, different conditions may be required to reduce and stabilize rhenium in its reduced state. These can be ascertained empirically by a person of ordinary skill in the art. Sulfhydryl-containing antibodies or antibody frag¬ ments The sulfhydryl containing whole antibodies or lower molecular weight antibody fragments can be labeled by the method of this invention. It is believed that sulfhydryl groups constitute at least a part of favored binding sites which exist on molecules and that by the method of this invention, the radiometals are preferentially exchanged from the radiometal-ligand complex to these favored sites on the molecules. The preferential labeling of these sites on the antibodies molecules results in labeled antibodies of exceptional stability. Whole antibodies (e.g. IgG) can be provided with sulfhydryl groups by reducing the antibodies with a reducing agent such as dithiothreitol DTT. Treatment with DTT exposes the sulfhydryl groups by reducing disulfide bridges. For most immunodiagnostic procedures, antibody fragments are preferred reagents. Antibody frag¬ ments have a number of advantages over whole anti¬ bodies for imaging procedures including, in general, more rapid distribution and accumulation at target site and less immunogenicity. Fab' fragments are monovalent antibody binding which contain free sulfhydryl groups (when maintained under non- oxidizing conditions) . These fragments can be labelled efficiently by the method of this inven¬ tion. Fab 1 fragments can be prepared from whole antibodies as follows: An antibody molecule is first treated with an endopeptidase such as pepsin to remove the Fc portion of the antibody molecule. The resultant F(ab) ' fragment is treated with a reducing agent such as DTT or cysteine to break disulfide bonds present on the F(ab) ' fragment resulting in exposed the sulfhydryl groups present on the molecules and thereby producing two Fab' molecules for each antibody molecule. Reaction Conditions The amount of reducing agent is the amount necessary to reduce the technetium to provide for the binding to the ligand in a reduced state. In a preferred mode, stannous chloride (SnCl ) is the reducing agent and can range from 1-1,000 ug/ml preferably about 30-500 ug/ml. The amount of saccharic acid (as potassium saccharate) can range from about 0.5 mg/ml up to the amount maximally soluble in the medium. Preferred amounts of saccharic acid range from 30-15 ug/ml. The amount of antibody (or fragment) can range from 0.01 to about 30 mg/ml preverably about .17 to about 1.5 mg/ml. Finally, technetium-99m in the form of pertechnetate can be in amounts used up to about 500 uCi/ml preferably about 1-50 mCi/ml. The amount of mCi per mg of antibody is preferably about 3-150. The reaction between the and the metal ion- transfer ligand complex is preferably carried out in an aqueous solution at a pH at which the protein is stable. By "stable", it is meant that the protein remains soluble and retains its biological activity. Normally, the pH for the reaction will be a pH from about 5 to 9, the preferred pH being about 6-8. The metal ion-transfer chelate complex and the antibody are incubated, preferably at a temperature from about 20 β C to about 60 β C, most preferably from about 20 β C to about 37 β C, for a sufficient amount of time to allow transfer of the metal ion from the ligand complex to the antibody. Generally, less than one hour is sufficient to complete the transfer reaction under these conditions. _ 7__ Kits For Performing The Method The reagent for performing the labeling method can be assembled in kits for convenient performance of the method in the clinic. At minimum, a kit for radiolabeling antibody or antibody fragments'"with the radiometals can consist of a one component a vial (sealed and sterile) containing a reducing agent (preferably stannous ions) and saccharic acid or a salt thereof. These kits can be used when the antibody or antibody fragment is provided by the user. Kits may also include a second vial containing the sulfhydryl-containing antibody or antibody fragment to be labeled. Two component kits would include: a. a vial containing a reducing agent and a water-soluble transfer ligand; and b. a sulfhydryl-containing antibody or antibody fragment under non-oxiding conditions. Kits can be designed to contain the appropriate antibody or antibody fragment(s) for any particular immunodiagnostic or immunotherapeutic procedure (some of which are discussed below) . The reagents in the kit can be provided in aqueous, lyophilized or from form. Lyophilized preparations can be diluted with aqueous medium upon use. The amount of reagents in each vial can vary according to the chosen parameters of the method (see above under Reaction Conditions) . When reagents are provided as a two component kit, as described, the labeling procedure can be performed simply as a two vial technique. Tech- netium-99m (for example, in the form of aqueous sodium pertechnetate) is added to the vial con¬ taining the reducing agent and the water-soluble ligand in aqueous solution. The contents of the two vials are then mixed and incubated for a time sufficient to effect labeling of the antibody or antibody fragment. The radiolabeled antibody or antibody fragment can then be used immediately without purification. One vial kits for performing the method The reagents for performing the present labeling method are assemlbled in single vial kit for convenient performance in the clinic. In one embodiment, the kit contains one vial (sealed and sterile) containing a sulfhydryl containing antibody or antibody fragment, a reducing agent (preferably stannous ions) and a water soluble ligand (preferably D-glucaric acid or a salt thereof) . These kits can be used when technetium-99m is provided by the user. The kits are designed to contain the appropriate antibody or antibody fragment(s) for any particular immunodiagnostic or immunotherapeutic procedure (some of which are discussed below) . The reagents in the kit can be provided in aqueous, frozen or lyophilized form. Lyophilized preparations can be diluted with aqueous medium upon use. The amount of reagents in each vial can vary according to the chosen parameters of the method (see above under Reaction Conditions) . The labeling procedure can be performed simply by adding technetium-99m (for example, in the form of aqueous sodium pertechnetate) to the vial containing the antibody or antibody fragment, reducing agent and, in a preferred embodiment, water soluble ligand. The contents of the vial are then mixed and incubated for a time sufficient to effect labeling of the antibody or antibody fragment. The radiolabeled antibody or antibody fragment can then be used immediately without purification. Use of the Labeled Antibodies in Immunodiagnostics Technetium-99m labeled antibodies or antibody fragments can be used in immunoscintigraphy. One important use is in the imaging of tumors. As mentioned, antibody fragments are preferred for most immunoscintigraphic techniques. Labeled Fab' fragments of tumor specific antibodies can be prepared and used to image primary or secondary tumors. In general, the technetium-99m labeled antibody fragment is prepared by forming an aqueous mixture of (i) 99m Tc; and (ii) a reducing agent and a water-soluble ligand; and contacting the mixture with an Fab 1 fragment specific for the tumor. The labeled Fab 1 fragment can then be injected parenterally (preferably intraveneously) into a subject. After injection, sufficient time is allowed for the labeled Fab' fragment to accumulate at the site of the tumor. The subject is then scanned with a gamma camera to detect the gamma emission of the technetium-99m and to thereby to obtain an image of the tumor. In this way the tumor can be localized and its size can be determined. Tumor-specific antibody fragments for use in these procedures can be derived from anticolorectal cancer antibody, antilung cancer antibody anti- ovarian cancer antibody, antibreast cancer antibody, and antiprostate cancer antibody. - Some specific examples of tumor specific antibodies which can be labeled by the method of this invention and used to image tumors are the monoclonal antibodies 17-1A and 19-9 (gastrointestinal) , CA 125 (ovarian) and 103D2 (breast) . Antibodies labeled by the method of this invention can be used to label myocardial infarcts. The imaging of myocardial infarcts to determine their size and location is described by Haber, U.S. Patent No. 4,421,735. In brief, employing the labelling method of this invention, an image of a mycocardial infarct in a subject can be obtained by first preparing a Tc-99m labeled myosin specific Fab' fragment by first forming an aqueous mixture of (i) ^Tc and (ii) a reducing agent and a water soluble ligand for ^ c; and then contacting the mixture with a myosin specific Fab' fragment. The labeled myosin specific fragment is then intra- veneously injected into a subject (for example, after coronary occlusion) . The labeled fragment is allowed to localize at the site of the infarct and an image of the infarct is obtained by scanning the area of the heart with a gamma camera. A preferred antibody for production of labeled myosin-specific Fab' fragments is the monoclonal antibody R11D10. In addition, fibrin-specific Fab' fragments can be labelled by the procedure of this invention to provide reagents for imaging blood clots. A Tc-99m labeled fibrin-specific fragment is prepared by forming an aqueous mixture of (i) Tc and (ii) a reducing agent and a water soluble li <gand for 99mTc and contacting the mixture with a fibrin specific 99 m . Fab' fragment. . The Tc-labeled fibrin specific fragment is injected into the subject. After allowing the fragment to localize at the site of the blood clot, the subject is scanned to obtain an image of the clot. Fibrin-specific antibodies which are not cross-reactive with fibrinogen are the preferred antibodies for this imaging technique. Antibody fragments specific for bacteria can be used in immunoscintigraphic techniques for obtaining an image of a bacterial abscess in a subject. For this purpose, anti-bacterial or anti-macrophage antibody fragments are employed. Antibodies against a common determinant of gram-negative bacteria (e.g., anti-lipid A antibody) can be used to image an abscess caused by a gram-negative microorganism. The antibody is labeled with technetium-99m as described above injected into the subject and allowed to localize at the abscess. The subject is then scanned with the photoscanning equipment to obtain an image of the abscess. Radioimmunotherapeutics Rhenium-labeled antibody or antibody fragments can be used to selectively deliver rhenium radioiso- topes to target cells in vivo. For example, rhenium labeled antibodies can selectively seek out and destroy cancer cells. For this purpose, tumor specific antibodies, such as those described above, can be labeled by the method of this invention and the resulting labeled antibody can be injected parenterally into a subjected afflicted with the tumor. The invention is further illustration by the following exemplification. Exemplification EXAMPLE 1 Radiolabeling of Antimyosin Antibody R11D10 Fab' with Technetium-99m using ^c ^ Saccharate Preparation of ^c-Saccharate Monopotassium saccharate (25 mg) was dissolved in 0.2M bicarbonate (1.0 ml) at pH 8.0. To 500 ul of saccharate solution was added 40 ul of stannous chloride (2.5 mg/ml) in 0.1M acetic acid followed by 500 ul of Tc-99m generator eluate (_60mCi/mg pro¬ tein) . The resulting solution was allowed to stand for 5 minutes at room temperature and then analyzed for radiochemical purity by paper chromatography (Whatman 3MM, 60% CH 3 CN:40%H 2 O) . Preparation of R11D10 Fab' Antimyosin monoclonal antibody R11D10 F(ab')_ 5mg/ml in 40mM TRIS pH 7.0 was reduced with lOmM DTT for 60 minutes at room temperature and then passed through a Sephadex G-25 column to remove the re¬ ducing agent. The resulting solution contained _80% Fab' fragment by gel-filtration HPLC. QQTTΪ Labeling of R11D10 Fab' using Tc-Saccharate Antimyosin antibody R11D10 Fab' (500 ul of a 1 mg/ml solution) in 50mM phosphate, 0.35 inM ZnCl- pH 6.5 was mixed with 500 ul of 99mTc-saccharate ' solution and allowed to stand at room temperature for 5-60 mi <nutes. The resulti•ng 99mTc-labeled protein was analyzed for radiochemical purity by paper chromatography (Whatman 3MM; 60% CH_CN: 40%H-O) and gel-filtration HPLC, and for immuno- reactivity using a myosin affinity column. EXAMPLE 2 The effect of Saccharate Concentration on the 99m Tc-Saccharate was prepared as described in Example 1 using different concentrations of potassium saccharate (0.09-12.25 mg/ml). The products were analyzed by paper chromatography (Whatman 3MM, 60% CH-CN/40% H O; "T!cO Rf = 1.0, 9m τc- saccharate, Rf = 0.4; 99ln Tc0 2 .x H 2 0, Rf = 0) . The data in Table I show that a concentration of 6 mg/ml potassium saccharate in 0.2M bicarbonate is suf¬ ficient to completely stabilize the reduced tech- netium. EXAMPLE 3 QQ-m Stability of Tc-Saccharate Samples of 99mTc-saccharate prepared from 6 and 12 mg/ml potassium saccharate were analyzed over a period of 7 hours. The results (Table II) indicated that the preparation from 12 mg/ml saccharate was more stable and was stable for a period of about 2 hours. EXAMPLE 4 The effect of Antibody Concentration on the Labeling of R11D10 Fab 1 using m Tc-Saccharate "'Tc-labeled R11D10 Fab' was prepared as described in Example 1 using various protein concen¬ trations up to 1250 ug/ml. After 1 hour, the reaction mixtures were analyzed by paper chroma- tography and HPLC. The results (Table III) showed that the radiochemical yield was dependent upon the concentration of the protein and that quantitative labeling could be obtained in 1 hour using at least 340 ug/ml. EXAMPLE 5 Evaluation of the Transfer of Technetium from "^Tc-Saccharate to Non-Reduced Antibody/Fragments compared to Fab' Fragment ' s 100 ul of whole antibody (2 mg/ml), F(ab') (2mg/ml) , Fab' (lmg/ml) of antimyosin antibody R11D10, antipancreatic antibody 19-9 and anti- colorectal antibody 17-lA were incubated with 100 ul QQTΓI Tc-saccharate solution at room temperatures for 1 and 3 hours. The resulting products were analyzed by paper chromatography. The results (Table IV) showed that the labeling of non-reduced anti¬ body/fragments was less than 5% versus quantitative labeling of the Fab' fragments. EXAMPLE 6 Labeli <ng of R11D10 Fab 1 Usi.ng 99mTC-glucoheptonate to Non-Reduced Antibody/Fragments Compared to Fab' Fragments R11D10 Fab' (1 mg/ml) was incubated with ^c-glucoheptonate at room temperature for one hour. Analysis by paper chromatography indicated quantitative transfer of the technetium to the antibody. EXAMPLE 7 Technetium-99m Labeling of Anti-Colorectal Antibody 17-lA Fab' and Antimyosin Antibody R11D10 Fab 1 Both antibody fragments were prepared and labeled as described in Example 1. Gel filtration HPLC analysis of the products after three hours at room temperature shows that for the 17-lA 35% of the protein was in the form of F(ab') 2 and 65% Fab' whereas for R11D10 23% was in the form of F(ab*)_ and 77% as Fab*. However, radioactive detection showed that 80% of the radioactivity was as¬ sociated with the Fab* peak for both antibodies. These results shows that the ^Tc-saccharate preferentially labels the Fab' fragments. EXAMPLE 8 Antibody Fragments . 99m Tc-labeled 17-lA Fab' and R11D10 Fab' were incubated at 37 β C for 1 hour in the presence and absence of human plasma. The results (Table V) showed that 80% of the technetium remained bound to the antibody for over 20 hours even in the presence of plasma. EXAMPLE 9 Immunoreactivity of 9mTc-labeled R11D10 Fab' Immunoreactivity of "'TC-RIIDIO Fab' prepara¬ tion was determined using a myosin affinity column. m Tc-17-lA was used as a control to estimate non-specific binding. Each labeled protein was incubated at 37 β C in the presence of human plasma. As shown in Table VI, the 99m Tc-labeled R11D10 Fab* was nearly 80% immunoreactive after 3 hours and 70% immunoreactive after 20 hours. The latter corresponded to 80% retention of immunoreactivity found immediately after labeling. EXAMPLE 10 Detection of Myocardial Infarct In The Dog Using 99m Tc-RllD10 Fab' Mongrel dogs (n=6) were anesthetized with I.V. pentobarbitol (30 mg/kg) , and respiration maintained on a Harvard respirator. Left thoracotomy was performed, the heart suspended in a pericardial cradle and a segment of the left anterior descending coronary artery approximately two thirds the dis¬ tance from the apex to the base was dissected free. The LAD was then occluded with a silk ligature. After three hours of LAD occlusion, the occlusive ligature was removed and reperfusion was establish¬ ed. At 15 minutes of reperfusion, 200 uCi of indium-Ill labeled R11D10 Fab-DTPA was injected and 30 seconds later, lOmCi of technetium labeled R11D10 Fab* was injected. Serial imaging with a gamma camera was initiated immediately upon tracer administration. Figure 1 shows the gamma scintigrams of a dog after 35 min. (upper left), 1.5 hours (upper right), 2.5 hours (lower left) and 5 hours (lower right) of antibody injection. Figure 2 shows the gamma images of the same dog as shown in Figure l, right lateral (upper left) , posterior anterior (lower right) views. Clear myocardial infarct images were observed in all views except the posterior position. More importantly, this figure shows no significant liver uptake 3 hours after injection of Tc-RIIDIO-Fab* . EXAMPLE 11 Biodistribution Studies of Technetium-99m Labeled R11D10 Fab' and of the Indium-Ill Labeled R11D10 Fab-DTPA in Mice Biodistribution studies were carried out in Balb/c mice. The mice (4 mice per group) were injected I.V. with either 150 uCi of technetium-99m labeled R11D10 Fab' (4 uCi/ug) or 10 uCi of indium- Ill labeled R11D10 Fab-DTPA (4 uCi/ug) . Groups of mice were sacrificed at 1,4 and 8 hours after receiving the injections and organs removed, weighed and counted. Table VII summarizes the percent injected dose per gram obtained for each preparation. The "^Tc-RIIDIO Fab 1 cleared rapidly from both the blood and liver. The percent of injected dose for Tc-RllDIO Fab' in the blood at 1 hour was 13.6% and dropped to 2.0% after eight hours. A similar drop in radioactivity was observed in the liver at the latter time point (6.4% in 1 hour and 2.4% in eight hours) . However, the indium-Ill labeled preparation showed much higher radioactivity in both liver (10.8%) and blood (5.1%) at the eighth hour after injection. EXAMPLE 12 R11D10 Fab' With Technetι <um-99m Using 99mTc- Arabonate Q Qjn Preparation of Tc-Arabonate Monopotassium arabonate (20 mg) was dissolved in 0.1M Na 2 CO_ (1.0 ml) at pH 10.0. To 500 ul of arabonate solution was added 500 ul of Tc-99m generator eluate (approx. 60mCi/mg protein) followed by 40 ul of stannous chloride (2.5 mg/ml) in 0.1M acetic acid. The resulting solution was allowed to stand at room temperature for 30 minutes and then adjusted to pH 7 using 1.0M hydrochloric acid. The sample was analyzed for radiochemical purity by paper chromatography (Whatman 3MM, 60% CH 3 CN:40% H 2 0) . * Preparation of R11D10 Fab' The same procedure as outlined in Example 1 was employed for preparation of R11D10 Fab*. QQ*m Preparation of R11D10 Fab' Using Tc-Arabonate Antimyosin antibody RllDlO Fab' (500 ul of a 1 mg/ml solution) in 50mM phosphate, 0.35 mM ZnCl , pH 6.5 was mixed with 500 ul of 99mTc-arabonate solu- tion and allowed to stand at room temperature for 60 QQTΠ minutes. The resulting Tc-labeled protein was analyzed for radiochemical purity as previously noted in Example 1. The results showed quantitative QQτrι ttrraannssffeerr of Tc to the protein under these con- ditions. EXAMPLE 13 Radiolabeling of Antimyosin RllDlO Fab' with Tech¬ netium 99m Using 99πι Tc-Tartarate QQTTΪ Preparation of Tc-Tartarate Disodium tartarate (230 Mg) was dissolved in 0.1M Na 2 C0 3 (1.0 ml) at pH 10.0. To 500 ul of tartarate solution ' was added 500 ul of Tc-99m generator eluate (approx. mCi/mg protein) followed by 40 ul of stannous chloride (2.5 mg/ml) in 0.1M acetic acid. The resulting solution was allowed to stand at room temperature for 30 minutes and then adjusted to pH 7 using 1.0M hydrochloric acid. The sample was analyzed for radiochemical purity as previously outlined in example 1 (see Page 13) . Preparation of RllDlO Fab' The same procedure as outlined earlier in Example 1 was used to prepared RllDlO Fab'. Preparation of RllDlO Fab' Using 99mTc-Tartarate Antimyosin antibody RllDlO Fab' (500 ul of a 1 mg/ml solution) in 50mM phosphate, 0.35 mM ZnCl , pH 6.5 was mixed with 500 ul of 99mTc-tartarate solu¬ tion and allowed to stand at room temperature for 60 minutes. The Tc-99m protein labeled product was analyzed as previously outlined in Example 1. The results showed quantitative transfer of QQTΠ Tc to the protein under these conditions. TABLES Table 1 Percent " of 99m Tc0 2 and 99m Tc-Saccharate After Incubation at Room Temperature for 1 Hr. at Various Concentrations of Saccharic Acid as Analyzed by Paper Chromatography. Saccharic Acid (mg/ml) % 99m Tc02 % 99lt *Tc- S accharate 12.25 .0 100.0 6.12 .0 100.0 3.06 11.5 88.5 1.53 19.5 80.5 0.76 24.4 75.6 0.38 30.0 70.0 0.19 41.0 59.0 0.09 57.0 43.0 Tablell Stability of ^Tc-Saccharate at room temperature Time 6.12 mg/ml 12.24 mg/ml Hours % Tc-SACC %Tc04~ % Tc-SACC %Tc04~ 1 95 ' 5 95 5 3 76 24 82 18 5 45 55 62 38 7 36 64 60 40 Table III Percent of 99m Tc-Labeled RllDlO Fab* After Labeling with "^c-Saccharate at Different Protein Concentration as Analyzed by Paper and HPLC Gel Filtration Chroma¬ tography. Protein Concentration % 99m Tb- •Labeled (ug/ml) Ab % 99ιn Tc-Saccharate 1250 100.0 0 340 100.0 0 165 72.0 28.0 133 66.2 33.8 100 67.0 33.0 33 53.0 47.0 0 0.0 100.0 Table IV Evaluation of the transfer of 99mtechneti<um as 9 m Tc-Saccharate to reduced vs. non-reduced antibody/fragments. % Labeling at % Labeling at Ab C1HR) (3HR) RllDlO IgG 3.6 3.6 RllDlO F(ab*) 2 1.6 1.0 RllDlO Fab-DTPA 4.4 3.2 RllDlO Fab' 100.0 100.0 19-9 IgG 4.0 4.1 19-9 F(ab) 2 4.3 2.4 19-9 Fab' 100.0 100.0 17-lA IgG 2.7 1.5 17-lA F(ab') 2 3.0 1.4 17-lA Fab' 100.0 100.0 Table V Stability of " m Tc-labeled 17-lA Fab* and ""re¬ labeled RllDlO Fab* in the Absence and Presence of Human Plasma % Tc-labeled Ab 3 hours 20 hours ' Absence Presence Absence Presence H. Plasma H. Plasma H. Plasma _ H. Plasma 17-lA Fab' 82 85 93 84 RllDlO Fab' 82 83 86 86 Table VI Immunoreactivity of Tc-labeled RllDlO Fab' % of Binding 0 hours 3 hours 20 hours Tc-17-lA Fab* 1.2 2.2 3.3 RllDlO Fab* 81 79 70 -37- Table VII Bio d istribtuion in % injected dose per gram of Indium labeled R l lD l O Fab-DTPA and Technetium-99m labeled RllDlO Fab ' at 1 , 4 , and 8 hours post injection in mice . One Hour Four Hours Eight Hours In-111- 99mTc-In-lll- 99m Tc- In-111- 99m Tc- Tlssue Blood 13.62±04.52 06.92±00.64 04.82101.00 05.11+00.49 02.02+00.48 Spleen 03.36 01.51 03.26±01.53 04.51103.04 04.97101.11 02.31101.17 Stomach 02.34±00.83 02.07±00.25 00.89100.35 01.51101.04 00.31+00.23 Intestine 02.74±01.00 02.72100.18 01.49100.04 02.53100.07 00.75100.24 Kidney 115.00±32.30 36.88109.38 81.10115.40 58.90105.10 57.67122.61 Liver 06.44101.87 08.82+00.91 03.68100.52 10.79+00.36 02.36+00.95 Lung 07.89±03.32 05.62101.60 03.60100.93 03.74100.87 01.61+00.57 Heart 08.77+04.16 03.00100.28 03.00101.13 03.10100.80 01.33+00.05 Muscle 01.31+00.17 01.53100.16 00.83100.32 01.82100.5 00.42100.11 Bone 00.63±00.24 00.90+00.17 00.92100.38 Not available A. Example 14: One Vial Method 1. Preparation of the T2Gls Fab* Antibody Fragment T2Gls F(ab') antibody fragment (162 mg) in tris buffer C15.5 ml, 0.05M, pH 8.0) with sodium chloride (0.1M) was treated with DTT (ImM) for 1-2 hours at ambient temperattire. The resulting mixture was purified by diafiltration under argon by exchange with 20 volumes of sodium phosphate buffer (0.05M, pH 6.4) containing sodium chloride (0.1M) and EDTA (0.001M) to yield a solution containing T2Gls Fab* C135 mg, concentration 1 mg/mL). Preparation of a Single Vial Kit for Tech_netiιjιτn-99m Labeling of T2Gls Antifibrin Antibody Fab' Fragment To a degassed solution (5 mL) of monopotassium D-glucaric acid (12.5 mg/mL, 0.05M) in potassium phosphate buffer (0.05M, pH 6.4) with EDTA (0.0005M), and sodium chloride (0.16M) was added stannous chloride solution (7.5 uL, 0.1 mg/mL in IN HC1). To this solution (4.7 mL) was added a solution of murine monoclonal antibody Fab' fragment derived from cell line T2Gls (0.312 mL, 8 mg/mL in 0.05M potassium phosphate buffer pH 6.4 containing 0.1M sodium chloride and 0.001M EDTA) prepared as described in subsection A.l above. After thorough mixing, portions (1.0 mL) were dispensed into serum vials, lyophilized then sealed with a rubber vial closure. 3. Radiolabeling the Antibody Fab' Fragment with Technetium-99m in a Single Vial Kit In a one vial procedure sodium ( xc) pertechnetate (1.0 mL, 20 mCi) was added to the vial of T2Gls Fab' described in subsection A.2 above. The solution was allowed to stand at ambient temperature and the mixture was analyzed at intervals using TM chromatography on Whatman 3MM paper eluting with acetonitrile:water (7:3). In this system, product remained at the origin while ( TC) pertechnetate and reduced complexed technetium-99m migrated off the origin. Completeness of reaction was determined by the percent of radiolabeled product at the origin. Further dilutions were made, if required, using saline (0.9%). The product of this one vial method was further analyzed as described in Section C below. B. Comparative Experiments: Two Vial Methods 1. Preparation of a Two Vial Kit for Technetium-99m Labeling of T2Gls Antifibrin Antibody Fab* Fragment a) Solution Formulation of the Antibody Fragment A vial was prepared to contain T2Gls Fab* (0.5 mg), prepared substantially as described above in subsection A.l above, in a buffer solution (1.0 mL) of potassium phosphate (0.05M, pH 6.4), sodium chloride (0.1M) and EDTA (0.001M). The vial was sealed with a rubber vial closure. b) Lyophilized Formulation of the Antibody Fragment A vial was prepared to contain T2Gls Fab' (0.5 mg), prepared substantially as described above in subsection A.l above, in a buffer solution (1.0 mL) of potassium phosphate (0.05M, pH 6.4), sodium chloride (0.05M), lactose (0.05M) and EDTA (0.0005M). The contents of the vial were lyophilized and then sealed with a rubber vial closure. 2. Preparation of the Stannous Composition for the Two Vial Method Using anaerobic conditions, vials were prepared to contain a solution (1.0 ml) of monopotassium D-glucaric acid (12.5 mg, 0.05 mmol), stannous chloride (150 ug, 0.79 umol) and sodium bicarbonate (16.8 mg, 0.2 mmol, pH 7.6). The contents of vial were lyophilized and then sealed with a rubber vial closure. 3. Radiolabeling the Antibody Fab' Fragment with Technetium-99m in Two Vial Kit In the two vial procedures sodium ( xc) pertechnetate (1.0 mL, 20 mCi) was added to the stannous composition described above. After 10 minutes 0.5 mL of this solution was added to the solution and lyophlized formulations of the T2Gls Fab' described in subsections a) and b) above. The product was analyzed as described in Section C. C. Comparison of Labeled T2Gls Antifibrin Antibody Fab' Fragments 1. Determination of the Immunoreactivity of the Technetium-99m Labeled T2Gls Fab' Immunoreactivity of the labeled antibody was tested by applying an aliquot of the antibody reaction mixtures to an affinity column (the first seven amino acids of the amino terminus of the beta chain of human fibrin, coupled to CNBr-Sepharose 6B). The volume of the packed bed was 1 mL. The column was eluted with 10 mL of 1% BSA in 0.01M sodium phosphate, 0.145M HaCl, pH 7.0, followed by elution with 10 ____• of 0.1M glycine, pH 2.5. During these elutions, 1 illiliter fractions were collected and counted in a Nal(Tl) well counter. The percent immunoreactivity was computed as: % immunoreactivity = total net counts eluted by glycine x 100 total net counts eluted by both solutions The results are shown in Tables VIII and IX. 2. Comparison of Labeling Rates of the One Vial and Two Vial Kits Table 1 also shows rates of labeling for the one vial and two vial kits as determined by % protein incorporation according to the paper chromatography technique described in subsection A.3 above. The results show that the one vial kit produces labeled product faster than the two vial kits. ■ Table VIII: Labeling Ratio of One Vial and Two Vial Kits Age When Storage Tested % Protein Incorporation Immunorer.c- Kit Temp (°C)(Davs ) _§_! Hi 2Q1 _____ tivitvf%. Two Vial 4° 7 HA 65 78 87 78 Solution Two Vial 4° 7 61 86 89 93 93 Lyophilized One Vial 4° 6 93 94 95 95 98 3. Comparison of the Stability of the One Vial and Two Vial Kits The stability .of the one vial and two vial kits were determined by % protein incorporation according to the paper chromatography described in subsection A.3 above at both 4 and 37 . The results are shown in Table 2. The results demonstrate that the one vial kit maintains superior labeling efficiency in the 12-17 day period when stored at 37 . Table IX: Stability of One Vial and Two Vial Kits Age When Storage Tested 7. Protein Incorporation Immunoreac- Kit Temp (°C)(Days) 1 15' 30' 60' tivitv(%"> Two Vial 4° 14 KA 75 84 92 82 Solution 37° 14 NA 35 45 59 40 Two Vial 4° 17 91 85 94 96 98 Lyophilized 37° 17 52 80 92 96 98 One Vial 37< 12 87 96 97 98 96 Biodistribution in Mice Mouse biodistribution of labeled antibody fragments prepared according to the one vial kit and two vial solution kit described above in Sections A and B was examined by injecting mice I.V. with the labeled fragments and determining the relative amounts of radiolabel accumulated in different tissues. The results are shown in Table X and Figures 3-7. The results show statistically significant differences favoring the one vial kit in every organ system evaluated. Table X ANTIFIBRIN T2G1S MOUSE BIODISTRIBUTION STUDY COMPARISON OF SINGLE VIAL AND DOUBLE VIAL PREPARATIONS MEAN PERCENT DOSE PER GRAM IN FIVE ANIMALS Organ Time After Single Vial Double Vial System Injection (Mean +/-* SD) (Mean +/- SD) p-value ( Hours) Blood 2.0 3.39 0.17 5.64 ± 0.53 <0.05 6.0 1.88 + 0.25 2.21 + 0.28 ns 24.0 0.48 £ 0.07 0.52 + 0.08 ns Heart 2.0 0.90 ± 0.11 1.34 £ 0.23 <0.05 6.0 0-56 + 0.06 0.58 £ 0.23 ns 24.0 0.45 £ 0.04 0.25 ± 0.03 <0.05 lungs 2.0 1.36 + 0.23 3.17 + 0.31 <0.05 6-0 0.88 £ 0.14 1.49 ± 0.42 <0.05 24.0 0.41 ± 0.05 0.44 ± 0.06 ns Liver 2.0 1.48 + 0.17 2.73 ± 0.41 <0.05 6.0 1.11 + 0.16 1.75 + 0.23 •CO.05 24.0 0.64 £ 0.03 0.65 ± 0.07 ns Spleen 2.0 0.54 £ 0.15 0.73 ± 0.09 ns 6.0 0.51 ± 0-12 0.45 £ 0.15 ns 24-0 0.51 ± 0.09 0.33 ± 0.02 •cθ.05 Kidneys 2.0 42.98 £ 7.65 58.00 ± 6.63 <0.05 6.0 37.70 ± 6.54 41.59 £ 9.13 ns 24.0 19.85 £ 1.83 16.60 ± 2.90 ns Stomach 2.0 0.34 + 0.07 0.94 £ 0.31 <0.05 6.0 0.85 ± 0.83 1.05 £ 0.52 ns 24.0 0.35 i 0.10 0.29 + 0.12 ns Small 2.0 1.40 0.44 3.63.+ 0.84 <0.05 Intestine 6.0 0.75 + 0.22 1.38 ± 0.34 <0.05 24.0 0.28 _fc 0.04 0.24 ± 0.05 ns Large 2.0 3.13 + 0.33 2.39 ± 0.89 ns Intestine 6.0 3.30 + 1.31 7.67 " + 1.96 <0.05 24.0 0.73 ± 0.19 0.40 + 0.11 <0.05 Muscle 2.0 0.19 + 0.03 0.46 ± 0.20 <0.05 6.0 0.15 0.06 0.18 ± 0.03 ns 24-0 0.29 + 0.03 0.11 ± 0.03 •CO.05 Gonads 2.0 0.36 0.09 1.35 ± 0.39 <0.05 6.0 0.29 ± 0.07 0.64 ± 0.14 <0.05 24.0 0.33 0.06 0.18 ± 0.03 •CO.05 4. Comparison of Plasma Stability of the One Vial and Two Vial Kits Labeled antibody was prepared as described in the above examples and comparative experiment (solution formulation). The "lc labeled T2Gls Fab' fragments (100 uL) were added to citrated plasma (50 uL). Table XI compares the plasma stability as determined by % protein incorporation at 37 of the products from the one vial and two vial kits versus control (no plasma added). The results show that the plasma stability of the one vial kit is better than the two vial kit. Table XI Plasma Stability of One Vial and Two Vial Kits No Plasma Added (Control) Plasma Added % Incorporation % Incorporation Kit 15' 3 hr 6 hr 24 hr 1 hr 2 hr 6 hr 24 hr Two Vial 92 69 90 78 88 78 73 69 Solution One Vial 88 90 84 89 90 88 86 83 Equivalents Those skilled in the art will recognize, or be able to ascertain using no more than routine experi¬ mentation, many equivalents to the specific embodi¬ ments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

Claims: CLAIMS 1. A method of labeling a sulfhydryl-containing antibody or antibody fragment with a ra'diometal selected from the group consisting of tech- netium-99m, rhenium-186, rhenium-188, rhenium- 189 and rhenium-191, comprising the steps of: a. forming a mixture of: i) the radiometal; and ii) a reducing agent and a water-soluble ligand, the ligand being capable of complexing the radiometal to form a soluble radiometal-ligand complex; b. contacting the mixture with a sulfhydryl-containing antibody or antibody fragment under conditions which permit transfer of the radiometal to the antibody or fragment to form a radiometal-labeled antibody or antibody fragment. 2. A method of Claim 1, wherein the sulfhydryl containing antibody is a reduced IgG. 3. A method of Claim 1, wherein the antibody fragment is*a Fab 1 fragment. 4. A method of Claim 1, wherein Fab 1 is produced by reducing an F(ab') 2 with DTT. 5. A method of Claim 1, wherein the water soluble ligand is a compound or salt thereof repre¬ sented by the formula: R l R-(CHX) m -(C) p -(CHΪ) n -R' R 2 where X arid Y are OH or NH . •_• / R and R' are independently H, COOH, or CH-OH, or R and R' taken together can form a ring or bi-or multidentate ligand; 1° m and n are 0-10 such that m+n is at least 2; R. and are independent H, lower alkyl, substituted lower alkyl, aryl or lower alkylaryl or R and R taken •1*5 together could complete carbonyl group; and p is 0 or 1 provided that when p is 1, m and n independently are at least 1. 0 6. A method of Claim 5, wherein the ligand is a compound or salt thereof represented by the formula: R-(CHOH) n -R' wherein R and R 1 are COOH or CH-OH and n=2-10, 7. A method of Claim 6, wherein the ligand is a polyhydroxydicarboxylic acid or salts thereof, of molecular weight less than about 10,000 daltons. 8. A method of Claim 7, wherein the ligand is selected from the group consisting of saccharic acid, glucoheptonic acid, tartaric acid, galactaric acid, arabonic acid and salts thereof. 9. A method of Claim 8, wherein the water soluble ligand is saccharic acid or a salt thereof. 10. A method of Claim 1, wherein the reducing agent is a stannous reducing agent. 11. A method of labeling a Fab* fragment with Technetium-99m, comprising the steps of: a. forming a mixture of; i) Tc-99m in an oxidized state; and ii) a composition comprising a reducing agent and a ligand of the formula: R l R-(CHX) ιn -(C) p -(CHY) n -R* R 2 where X and Y are OH or NH_ . R and R* are independently H, COOH, or CH 2 OH, or R and R' taken together can form a ring or bi-or multidentate ligand; and n are 0-10 such that m+n is at least 2; R. and R, are independent H, lower alkyl, substituted lower alkyl, aryl or lower alkylaryl or R. and R taken together could complete carbonyl group; and p is 0 or 1 provided that when p is 1, m and n independently are at least 1. b. contacting the mixture with an Fab' fragment to produce a Tc-99m labeled Fab' fragment. 12. A method of Claim 11, wherein the Fab* fragment is produced by reducing an F(ab*) fragment. 13. A method of Claim 11, wherein the reducing agent is a stannous reducing agent. 14. A method of Claim 12, wherein the stannous reducing agent is stannous chloride. 15. A method of- Claim 11, wherein the Tech- netium-99m is used as a pertechnetate. 16. A method of Claim 11, wherein the ligand is represented by the formula: R- (CHOH) n -R ' wherein R and R' are COOH or CH 2 OH, and n=2-10 17. A method of Claim 6, wherein ligand is a polyhydroxydicarboxylic acid or salt thereof having a molecular weight of less than about 10,000 daltons. 18. A method of Claim 7, wherein the ligand is selected from the group consisting of saccharic acid, glucoheptonic acid, tartaric acid, muccic acid, arabonic acid and salts thereof. 19. A method of Claim 8, wherein the ligand is saccharic acid or a salt thereof. 20. A method of Claim 11, wherein the Fab' fragment is derived from an anti-myosin, anti-fibrin, or anti-platelet antibody. 21. A method of Claim 11, wherein the Fab* fragment is derived from an anti-tumor antibody. 22. A method of Claim 21, wherein the anti-tumor antibody is an anti-colorectal cancer antibody, anti-ovarian cancer antibody, anti-lung cancer antibody, anti-breast cancer antibody or anti-prostate cancer antibody. 23. A method of Claim 11, wherein the Fab' fragment is derived from an antibacterial or anti-macro- phage antibody. 24. A method of labeling a Fab' fragment with technetium-99m, comprising the steps of: a. reacting aqueous pertechnetate-99m with a water-soluble ligand in the presence of a reducing agent to form a stabilized complex of the ligand and Technetium-99m in a reduced state; and b. thereafter, reacting a Fab' fragment with the complex to form a Tc-99m-labeled Fab' fragment. 25. A method of Claim 24, wherein the reducing agent is stannous ions and the ligand is saccharic acid or a salt thereof. 26. A method of labeling a sulfhydryl containing antibody or antibody fragment with tech- netium-99m, comprising the steps of: a - forming an aqueous mixture of pertech- nenate-99m, a stannous reducing agent and saccharic acid; b. combining the mixture and a sulhydryl containing antibody or antibody fragment to produce a Technetium-99m-labeled antibody or antibody fragment. 27. A method of Claim 26, wherein the antibody fragment is a Fab' fragment. 28. A method for labeling a Fab' fragment with technetium-99m, comprising: a. adding sodium pertechnetate-99m to a first vial containing an aqueous ..solution of stannous reducing agent and saccharic acid or a salt thereof; and b. thereafter mixing the contents of the first vial with the contents of a second vial containing an aqueous solution of an Fab* fragment under non-oxidizing condi¬ tions. 29. A composition for directly radiolabeling antibodies or antibody fragments, comprising a mixture of a reducing agent and saccharic acid or a salt thereof. 30. A composition of claim 29, wherein the reducing agent is a stannous reducing agent. 31. A composition of claim 30, wherein the stannous reducing agent is stannous chloride. 32. A kit for radiolabeling an antibodies or antibody fragments, comprising a sealed, sterile vial containing a mixture of a reducing agent and saccharic acid or a salt thereof. 33. A kit of Claim 32, wherein the reducing agent is a stannous reducing agent. 34. A kit of Claim 33, wherein the stannous re¬ ducing agent is stannous chloride. 35. A kit for radiolabeling an antibody or antibody fragment comprising: a. a vial containing a mixture of a reducing agent and a water soluble ligand com¬ prising a compound or salt thereof repre- sented by the formula: R l R-(CHX) m -(C) p -(CHY) n -R* R 2 where X and Y are OH or NH_; R and R* are independently H, COOH, or CH OH, or R and R* taken together can form a ring or bi-or multidentate ligand; m and n are 0-10 such-that m+n is at least 2; R. and R- are H, lower alkyl, sub- stituted lower alkyl, aryl or lower akylaryl; and p is 0 or 1 provided that when p is 1, m and n independently are at least 1; and b. a vial containing Fab' fragment under nonoxiding conditions. 36. A kit of claim 35, the reducing agent is a stannous reducing agent. 37. A kit of Claim 36, wherein the ligand is represented by the formula: R-(CHOH) n -R' wherein R and R* are COOH or CH_OH, and n=2-10 38. A kit of Claim 37, wherein ligand is a polyhydroxydicarboxylic acid of molecular weight less than about 10,000 daltons. 39. A kit of Claim 38, wherein the ligand is selected from the group consisting of saccharic acid, tartariσ acid, glucoheptonic acid, galactaric acid, arabonic acid and salts thereof. 40. A kit of Claim 39, wherein the ligand is saccharic acid or a salt thereof. 41. A kit for radiolabeling a Fab' fragment with technetium-99m, comprising: a. a vial containing a aqueous mixture of a reducing agent and a salt of saccharic acid; and b. a vial containing Fab' under non-oxidizing conditions. 42. A kit of Claim 41, wherein the reducing agent is a stannous reducing agent. 43. A kit of Claim 41, wherein the Fab' fragment is derived from an anti-myosin, anti-fibrin or anti-platelet antibody. 44. A kit of Claim 41, wherein the Fab' fragment is derived from an anti-tumor antibody. 45. A method of Claim 44, wherein the anti-tumor antibody is an anti-colorectal cancer antibody, anti-ovarian cancer antibody, anti-breast cancer antibody or anti-prostate cancer anti¬ body. 46. A method of Claim 41, wherein the Fab' fragment is derived from an antibacterial or anti- acro- phage antibody. 47. A method of obtaining a scintigraphic image of a tumor in a subject comprising the steps of; a. preparing a Tc-99m-labeled Fab 1 fragment specific for the tumor by forming an aqueous mixture of; (i) 99m Tc0 4 " ; and (ii) a reducing agent and a water-soluble ligand; and contacting the mixture with an Fab » fragment specific for the tumor; b. injecting parenterally the labeled Fab' fragment into the subject; c. allowing the labeled Fab' fragment to localize at the tumor; and d. scanning the subject with a gamma camera to obtain an image of the tumor. 48. A method of Claim 46, wherein the water soluble ligand is a compound of salt thereof repre¬ sented by the formula: R l R-(CHX) ro -(C) p -(CHY) n -R « R 2 where X and Y are OH or NH_ . R and R' are independently H, COOH, or CH 2 OH, or R and R » taken together can form a ring or bi-or multidentate ligand; m and n are 0-10 such that m-t-n is at least 2; R. and R 2 are independent H, lower alkyl, substituted lower alkyl, aryl or lower alkylaryl or R. and R taken together could complete carbonyl group; and p is 0 or 1 provided that when p is 1, m and n independently are at least 1. 49. A method of Claim 48, wherein the ligand is a compound or salt thereof represented by the formula: R-(CHOH) n -R* wherein R and R' are COOH or CH 2 OH and n=2-10. 50. A method of Claim 49, wherein the ligand is a polyhydroxydicarboxylic acid of molecular weight less than about 10,000 daltons or a salt thereof. 51. A method of Claim 50, wherein the ligand is selected from the group consisting of saccharic acid, glucoheptonic acid, tartaric acid, muccic acid, arabonic acid or salts thereof. 52. A method of Claim 51, wherein the ligand is saccharic acid or a salt thereof. 53. A method of Claim 47, wherein the reducing agent is a stannous reducing agent. 54. A method of Claim 47, wherein the Fab* is derived from an anti-tumor antibody. 55. A method of Claim 47, wherein the anti-tumor antibody is an anti-colorectal cancer antibody, anti-ovarian cancer antibody, anti-breast cancer antibody or anti-prostate cancer anti¬ body. 56. A method of obtaining a scintigraphic image of a tumor in a subject, comprising the steps of: a. preparing a Tc-99m-labeled Fab* fragment specific for the tumor by forming an aqueous mixture of; (i) 99m Tc0 4 ; and (ii) a reducing agent and saccharric acid or a salt thereof; and contacting the mixture with an Fab* fragment specific for the tumor; b. injecting parenterally the labeled Fab' fragment into the subject; c. allowing the labeled Fab' fragment to localize at the tumor; and d. scanning the subject with a gamma camera to obtain an image of the tumor. 57. A method of Claim 56, wherein the Fab* fragment is derived from an anti-tumor antibody. 58. A method of Claim 57, wherein the anti-tumor antibody is an anti-colorectal cancer antibody, anti-ovarian cancer antibody, anti-breast cancer antibody, anti-lung cancer antibody or anti-prostate cancer antibody. 59. A method of obtaining a scintigraphic image of bacterial abscess in a subject, comprising; a. preparing a Tc-99m-labeled antibacterial Fab* fragment by forming an aqueous mixture of; (i) 99m Tc0 4 " ; and (ii) a reducing agent and a water-soluble ligand for ^Tc; and contacting the mixture with an antibac- terial Fab* fragment; b. injecting parentally the labeled Fab' fragment into the subject; c. allowing the labeled Fab' fragment to localize at the abscess; and d. scanning the subject with a gamma camera to obtain an image of the abscess. 60. A method of Claim 59, wherein the water soluble ligand is a compound or salt thereof repre¬ sented by the formula: R l R-(CHX) m -(C) p -(CHY) n -R* R 2 where X and Y are OH or NH_. __ - R and R* are independently H, COOH, or CH 2 OH, or R and R' taken together can form a ring or bi-or multidentate ligand; m and n are 0-10 such that m+n is at least 2; .^ and 2 are independent H, lower alkyl, substituted lower alkyl, aryl or lower alkylaryl or R. and R taken together could complete carbonyl group; and p is 0 or 1 provided that when p is 1, m and n independently are at least 1. 61. A method of Claim 60, wherein the ligand is a compound or salt thereof represented by the formula: wherein R and R' are COOH or CH 2 OH and n=2-10. 62. A method of Claim 61, wherein the ligand is a polyhydroxydicarboxylic acid of molecular weight less than about 10,000 daltons. 63. A method of Claim 62, wherein the ligand is selected from the group consisting of saccharic acid, glucoheptonic acid, galactaric acid, tartaric acid, and arabonic acid. 64. A method of Claim 63, wherein the transfer ligand is saccharic acid or a salt thereof. 65. A method of Claim 63, wherein the Fab' is derived from an anti-bacterial antibody. 66. A method of Claim 63, wherein the Fab* is derived from an anti-macrophage antibody. 67. A method of obtaining an image of a mycocardial infarct in a subject, comprising the steps of: a. preparing a Tc-99m; labeled myosin spe¬ cific Fab* fragment by forming an aqueous mixture of: (i) 99m Tc0 4 " and (ii) a reducing agent and a water soluble ligand for " c,* and contacting the ' mixture with a myosin specific Fab 1 fragment; b. injecting the ^Tc-labeled myosin spe¬ cific fragment into the subject; c. allowing the fragment to localize at the site of the infarct; and d. scanning the subject in the area of the heart to obtain an image of the infarct. 68. A method of Claim 67, wherein the water-soluble ligand is saccharic acid or a salt thereof. 69. A method of obtaining an image of a blood clot in a subject, comprising the steps of: a. preparing a Tc-99m labeled fibrin specific Fab' fragment by forming an aqueous mixture of: (i) 99m cO -' * and (ii) a reducing agent and a water soluble ligand for "'TC; and contacting the mixture with a fibrin specific Fab* fragment; Q TΠ ■ • b. injecting the Tc-labeled fibrin spe¬ cific fragment into the subject; c. allowing the fragment to localize at the site of the blood clot; and d. scanning the subject to obtain an image of the clot. 70. A method of tumor iitimunotherapy, comprising the steps of: a. preparing a rhenium-labeled tumor specific antibody fragment by forming an aqueous mixture of: (i) a perrhenate of rhenium-186, rhe¬ nium-188, rhenium-189 or rhenium-191; and (ii) a reducing agent and a water-soluble ligand for rhenium; and contacting the mixture with tumor- specific fragment to form a rhenium- labeled fragment; and b. injecting the rhenium labeled fragment into a subject. 71. A one vial method for labeling a sulfhydryl containing antibody or antibody fragment with technetium-99m comprising contacting in a vial an antibody mixture comprised of a sulfhydryl containing antibody or antibody fragment and a reducing agent with technetium-99m in an oxidized state. 72. A method according to Claim 71, wherein the antibody mixture further comprises a water soluble ligand. 73. A method according to Claim 72, wherein the sulfhydryl containing antibody is reduced to IgG. 74. A method according to Claim 71, wherein the antibody fragment is a Fab* fragment. 75. A method according to Claim 74, wherein Fab' is produced by reducing an F(ab') 2 with DTT. 76. A method according to Claim 71, wherein the antibody mixture is reconsituted from a lyophilized form. 77. A method according to Claim 72, wherein the water soluble ligand is a comound or salt thereof represented by the formula: R l R-(CHX) m -(C) p -(CHY) n -R « R 2 where X and Y are OH or NH 2 ; R and R' are independently H, COOH, or CH 2 0H, or R and R' taken together can form a ring or bi- or multidentate ligand; m and n are 0-10 such that +n is at least 2; R. and R 2 are independent H, lower alkyl, substituted lower alkyl, aryl or lower alkylaryl or R- and R 2 taken together could complete carbonyl group; and p is 0 or 1 provided that when p is 1, m and n independently are at least 1. 78. A method according to Claim 77, wherein the ligand is a compound or salt thereof repre¬ sented by the formula: R-(CH0H) n -R* wherein R and R* are COOH or CH 2 OH and n=2-10. 79. A method according to Claim 78, wherein the ligand is a polyhydroxydicarboxylic acid or salts thereof, of molecular weight less than » about 10,000 daltons. 80. A method according to Claim 79, wherein the ligand is selected from the group consisting of D-glucaric acid, glucoheptonic acid, tartaric acid, galactaric acid, arabonic acid and salts thereof. 81. A method according to Claim 80, wherein the water soluble ligand is D-glucaric acid or a salt thereof. 82. A method of Claim 1, wherein the reducing agent is a stannous reducing agent. 83. A method, for labeling a Fab' antibody fragment with technetium 99m comprising: a. providing a vial containing a lyophilized mixture of: i. an Fab" antibody fragment; ii. a stannous reducing agent; and iii. D-glucaric acid; and b. adding to the vial an aqueous solution of sodium ( ^c) pertechnetate. 84. A one vial kit for labeling a sulfhydryl containing antibody or antibody fragment with technetium-99m comprising an antibody mixture comprised of a sulfhydryl containing antibody or antibody fragment and a reducing agent, whereby the antibody mixture is contained with technetium-99m in an oxidized state to provide labeled antibody or antibody fragment. 85. The one vial kit of Claim 84, wherein the antibody mixture further contains a water soluble ligand. 86. The one vial kit of Claim 85, wherein the antibody mixture is supplied in a lyophilized form.

Inventors: BUTTRAM SCOTT, DEAN RICHARD T, LISTER-JAMES JOHN, MATTIS JEFFREY A, PAK KOON YAN, BUTTRAM, SCOTT, DEAN, RICHARD., T., LISTER-JAMES, JOHN, MATTIS, JEFFREY, A., PAK, KOON, YAN
Applicants: CENTOCOR CARDIOVASCULAR IMAGIN, CENTOCOR CARDIOVASCULAR IMAGING PARTNERS, L.P.
Application year: 1988
Main classification: A61K49
IPC codes: A61K39, A61K51, C07K1, C07K14, C07K16